MDK and neoplasm: Interestingly, Mdk and Igfbp7, the tumor-intrinsic factors associated with resistance to tipifarnib (Fig. 3e, f), were also upregulated in MyoCAFs in the tipifarnib-treated group (Fig. 4d, e), implying key roles for these two targets in dormant tumor cells.